烟囱腔内修复术治疗肾上主动脉病变:PERICLES注册研究结果
基于PERICLES注册研究,回顾性分析67例接受烟囱腔内修复术(ch-EVAR)治疗的肾上主动脉病变(SRAP)患者,多数置入3个烟囱移植物。中位随访24个月,30天死亡率为6.1%,总死亡率为16.4%,1年生存率为87.4%。I A型内漏发生率为13.4%,烟囱闭塞见于6条肾动脉(9.5%)和2条肠系膜上动脉(3.2%),缺血性卒中或短暂性脑缺血发作为2.9%。
要点
- ch-EVAR治疗SRAP的中期结果安全,但I A型内漏、烟囱闭塞和缺血性卒中发生率高于单烟囱证据。
- 30天死亡率为6.1%,总死亡率为16.4%,1年生存率为87.4%。
- 动脉瘤囊直径从70.5±19.3 mm显著减小至66.9±20.6 mm(P < .001)。
核心结论
- ch-EVAR治疗SRAP的中期应用看似安全,适用于破裂风险病变及EVAR后I A型内漏的锚定区延长。
- 但I A型内漏、烟囱移植物闭塞和缺血性卒中发生率高于现有单烟囱证据。
研究设计与样本
- 回顾性分析PERICLES注册研究中2008年至2014年间13个欧美中心517例接受ch-EVAR治疗的复杂主动脉病变患者。
- 其中67例(12.9%)为肾上主动脉病变(SRAP),83.5%为择期,16.5%为急诊。
主要发现
- 95.5%的患者接受3个烟囱移植物,4例接受4个;共置入204个烟囱移植物。
- 中位随访24个月(范围0.1-67.0天),30天死亡率为6.1%(4例),总死亡率为16.4%(11例)。
- 1年总生存率为87.4%(范围79.5%-96.0%),2年及以后为81.8%(范围72.2%-92.2%)。
- I A型内漏术中见于9例(13.4%),7例成功治疗(技术成功率97.1%)。
- 动脉瘤囊直径从70.5±19.3 mm显著减小至末次随访时66.9±20.6 mm(P < .001)。
关键数值与推荐
- 30天死亡率为6.1%(4例),总死亡率为16.4%(11例)。
- 1年生存率为87.4%(范围79.5%-96.0%),2年及以后为81.8%(范围72.2%-92.2%)。
- I A型内漏发生率为13.4%(9例),技术成功率为97.1%。
- 动脉瘤囊直径从70.5±19.3 mm减小至66.9±20.6 mm(P < .001)。
- 烟囱闭塞率:肾动脉9.5%(6条),肠系膜上动脉3.2%(2条);缺血性卒中或短暂性脑缺血发作2.9%(2例)。
临床怎么用
- ch-EVAR可用于治疗SRAP,包括破裂风险病变和EVAR后I A型内漏的锚定区延长。
- 需警惕I A型内漏、烟囱闭塞和缺血性卒中风险,术后应密切监测。
- 烟囱闭塞后可通过腔内技术成功补救,本研究中所有闭塞的肠系膜上动脉移植物均成功补救。
局限性
- 回顾性研究设计。
- 样本量较小(67例SRAP患者)。
- 随访时间有限(中位24个月),需更长随访和更多病例确定该治疗的准确性能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prevailing evidence calls for using chimney/snorkel endovascular repair (ch-EVAR) with one or two chimney grafts. No studies up to now focus on its applicability and results for the treatment of suprarenal aortic pathologies (SRAP). Hence, we evaluated the clinical and radiologic results of ch-EVAR treatment for SRAP placing three or more chimney grafts within the PERICLES Registry. METHODS: Data from 517 patients suffering complex aortic pathologies treated by ch-EVAR between 2008 and 2014 at 13 European and U.S. centers were retrospectively reviewed and analyzed. RESULTS: Sixty-seven ch-EVAR-treated patients (12.9% of the entire PERICLES cohort) presented SRAP (83.5% elective, 16.5% urgent). The majority of patients (95.5%) received three chimney grafts; four patients received four chimney grafts. The Endurant device was the most commonly used (35.8%) followed by the Zenith abdominal endograft (19.4%). Overall, 204 chimney grafts were placed (56.7% covered self-expandable, 40.3% covered balloon-expandable stents, and 10.4% bare metal balloon-expandable stents). At a median follow-up of 24 months (range, 0.1-67.0 days), 30-day mortality was 6.1% (4 patients), and the overall mortality was 16.4% (11 patients). Overall survival was 87.4% (range, 79.5%-96.0%) at 1 year, 81.8% (range, 72.2%-92.2%) at 2 years and thereafter. Type IA endoleak was noted in nine patients (13.4%) intraoperatively and successfully treated in seven cases (97.1% technical success). Aneurysm sac diameter significantly decreased from 70.5 ± 19.3 mm to 66.9 ± 20.6 mm (P < .001) at last follow-up. Ischemic stroke or transient ischemic attack were noted in two patients (2.9%). Chimney occlusion was detected in six renal arteries (9.5%) and two superior mesenteric arteries (3.2%). No patients required chronic hemodialysis. All occluded superior mesenteric artery grafts were successfully rescued using endovascular approaches. CONCLUSIONS: The midterm use of ch-EVAR for the treatment SRAP seems to be safe, highlighting its applicability for the treatment of rupture threatening pathologies and seal zone lengthening as in type IA endoleaks after EVAR. However, the incidence of type IA endoleaks, chimney graft occlusions, and ischemic stroke rates is higher compared with the prevailing single chimney evidence. Longer follow-up with more cases is needed to establish the exact performance of this treatment in SRAP.
引用
- Taneva GT, Criado FJ, Torsello G, et al. Results of chimney endovascular aneurysm repair as used in the PERICLES Registry to treat patients with suprarenal aortic pathologies. J Vasc Surg. 2019. PMID: 31611110. doi:10.1016/j.jvs.2019.08.228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。